Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.
Bougherara H, Némati F, Nicolas A, Massonnet G, Pugnière M, Ngô C, Le Frère-Belda MA, Leary A, Alexandre J, Meseure D, Barret JM, Navarro-Teulon I, Pèlegrin A, Roman-Roman S, Prost JF, Donnadieu E, Decaudin D. Bougherara H, et al. Among authors: pelegrin a. Oncotarget. 2017 Oct 7;8(59):99950-99965. doi: 10.18632/oncotarget.21556. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245952 Free PMC article.
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P, Fontayne A, Barret JM, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget JP, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost JF, Pèlegrin A, Navarro-Teulon I. Estupina P, et al. Among authors: pelegrin a. Oncotarget. 2017 Jun 6;8(23):37061-37079. doi: 10.18632/oncotarget.15715. Oncotarget. 2017. PMID: 28427157 Free PMC article.
Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C, Bazin H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, Garambois V, Poul MA, Mondon P, Barret JM, Mathis G, Prost JF, Pèlegrin A, Chardès T. Le Clorennec C, et al. Among authors: pelegrin a. Mol Cancer Ther. 2017 Jul;16(7):1312-1323. doi: 10.1158/1535-7163.MCT-16-0886. Epub 2017 May 15. Mol Cancer Ther. 2017. PMID: 28507002 Free article.
Anti-HER2 vaccines: new prospects for breast cancer therapy.
Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Ladjemi MZ, et al. Among authors: pelegrin a. Cancer Immunol Immunother. 2010 Sep;59(9):1295-312. doi: 10.1007/s00262-010-0869-2. Epub 2010 Jun 8. Cancer Immunol Immunother. 2010. PMID: 20532501 Free PMC article. Review.
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.
Le Clorennec C, Lazrek Y, Dubreuil O, Sampaio C, Larbouret C, Lanotte R, Poul MA, Barret JM, Prost JF, Pèlegrin A, Chardès T. Le Clorennec C, et al. Among authors: pelegrin a. Cell Commun Signal. 2019 Aug 23;17(1):106. doi: 10.1186/s12964-019-0413-8. Cell Commun Signal. 2019. PMID: 31443721 Free PMC article.
General overview of radioimmunotherapy of solid tumors.
Navarro-Teulon I, Lozza C, Pèlegrin A, Vivès E, Pouget JP. Navarro-Teulon I, et al. Among authors: pelegrin a. Immunotherapy. 2013 May;5(5):467-87. doi: 10.2217/imt.13.34. Immunotherapy. 2013. PMID: 23638743 Review.
166 results